Giroctocogene fitelparvovec (SB-525)
Hemophilia A
Phase 3Active (AFFINE Study)
Key Facts
About Sangamo Therapeutics
Sangamo Therapeutics is a public biotech company focused on translating groundbreaking zinc finger technology into genomic cures for severe diseases with high unmet need. The company has built a diversified pipeline of wholly-owned and partnered programs, primarily in neurology, with key assets in late-stage clinical development for Fabry disease and hemophilia A. Sangamo's strategy combines internal development of neurology-focused therapies with strategic collaborations with major pharmaceutical companies to expand its reach and validate its platform technology.
View full company profileOther Hemophilia A Drugs
| Drug | Company | Phase |
|---|---|---|
| Hemlibra (emicizumab) | Chugai Pharmaceutical | Approved |
| Factor VIII Products | CSL | Commercial |
| Gene Therapy | BioMarin Pharmaceutical | Commercial |
| Human Coagulation Factor VIII | Shanghai RAAS Blood Products | Approved |
| Recombinant Coagulation Factor VIII | Shanghai RAAS Blood Products | Phase 3 |
| Factor VIII | Tiantan Bio | Approved |
| Recombinant Factor VIII | Hualan Biological Engineering | Pre-clinical |